A public offering of 12.5 million shares of common stock and warrants to buy up to 12.5 million additional shares has been priced by Interpace Diagnostics in hopes of obtaining $13.7 million in gross proceeds. The company intends to use the $12.7 million net proceeds as working capital, as well as for general corporate functions, payment of legacy contract sales organization obligations and trade payables.
Offering could pull in $13.7M for Interpace Diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.